1. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.
- Author
-
Lange, Naomi F., Graf, Vanessa, Caussy, Cyrielle, and Dufour, Jean-François
- Subjects
- *
NON-alcoholic fatty liver disease , *PEROXISOME proliferator-activated receptors , *TYPE 2 diabetes , *PEOPLE with diabetes , *NUCLEAR receptors (Biochemistry) , *CARDIOVASCULAR diseases , *SKELETAL muscle , *ADIPOSE tissues - Abstract
Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause a significant burden worldwide and therapeutic strategies are needed. This review provides an overview of the evidence on PPAR-targeted treatment of NAFLD and NASH in individuals with type 2 diabetes mellitus. We considered current evidence from clinical trials and observational studies as well as the impact of treatment on comorbid metabolic conditions such as obesity, dyslipidemia, and cardiovascular disease. Future areas of research, such as possible sexually dimorphic effects of PPAR-targeted therapies, are briefly reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF